Status
Conditions
Treatments
About
The Auryon Laser Atherectomy System has been cleared by the FDA to treat infrainguinal arterial disease including in-stent restenosis
Full description
To observe the treatment effects of the Auryon Laser Atherectomy System in treating Infrapopliteal peripheral arterial disease
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Subject is 18 years of age or older. 2. Critical limb ischemia (CLI) in the target limb from the distal segment (P3) of the popliteal artery to the ankle joint prior to the study procedure with Rutherford Category 4-5 in the target limb from the distal segment (P3) of the popliteal artery to the ankle joint prior to the study procedure.
Patient has signed approved informed consent. 4. Patient is willing to comply with the follow-up evaluations Angiographic Inclusion Criteria
Target lesions(s) must be viewed angiographically and have ≥50% stenosis. More than one lesion can be included in the same vessel.
Only 1 target vessel is included in the study.
Intraluminal crossing of the lesion. If this is not certain, IVUS may be used to verify this per operator's discretion.
Target Lesion reference vessel diameter (RVD) between 1.5 mm - 4.5 mm. by investigator estimate.
Exclusion criteria
Target lesion is in a vessel graft or synthetic graft.
Subjects requiring dialysis.
Subject is unable to understand the study or has a history of non-compliance with medical advice.
Subject is unwilling or unable to sign the Informed Consent Form (ICF)
Subject is currently enrolled in another clinical investigational study that might clinically interfere with the current study endpoints.
Subject has a known sensitivity to contrast media and the sensitivity cannot be adequately pre-medicated for.
Subject has a CVA or TIA within 4 weeks prior to the Auryon procedure.
Planned Use of another debulking device or specialty balloons before or after the Auryon laser during the index procedure
Patient has any planned surgical intervention or endovascular procedure ≤14 days after the index procedure or had these procedures in the past 14 days
Life expectancy of less than one year judged by the investigator
Patient unable to take anticoagulant or antiplatelet agents
Platelet count less than 80,000K or bleeding disorders
Subject is suspected of having an active systemic infection.
Patient enrolled once already in the protocol
Planned major amputation of either leg.
Acute limb ischemia
Current Covid-19 Infection or history of Covid-19 in the past 30 days.
Subject is pregnant or planning on becoming pregnant.
Vulnerable patients who are unable to give informed consent on their own Pregnant and Vulnerable Populations. There will be no female patients who are pregnant or any vulnerable populations enrolled in the study.
Subject experiencing ongoing cardiac problems that per the investigator judgment would not make the subject ideal per the procedure
Subject has evidence of intracranial or gastrointestinal bleeding within the past 3 Angiographic Exclusion Criteria
Failure to treat clinically significant inflow lesions in the contralateral iliac, ipsilateral iliac, femoral, or P1-P2 segments of the popliteal arteries with ≤ 30 % residual stenosis, and no serious angiographic complications (e.g., embolism) 2. Failure to successfully treat significant non-target infra-popliteal lesions prior to treatment of the target lesion. Successful treatment is defined as obtaining ≤ 50 % residual stenosis with no serious angiographic complications (e.g., embolism).
Failure to successfully cross the guidewire across the target lesion; successful crossing is defined as tip of the guidewire distal to the target lesion in the absence of flow limiting dissections or perforations.
In-stent restenosis.
Primary purpose
Allocation
Interventional model
Masking
60 participants in 1 patient group
Loading...
Central trial contact
Gail Shammas; NIcolas Shammas
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal